Clinicopathologic characteristics and prognostic impact of atypical EGFR mutations in completely resected lung adenocarcinoma
-
Published:2022-12
Issue:
Volume:177
Page:53-62
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
She Yunlang,
Li Shenghui,
Deng Jiajun,
Ren Yijiu,
Zhao MengmengORCID,
Zhong Yifan,
He Yiming,
Chen Qiankun,
Zhao Deping,
Zhu Yuming,
Hou Likun,
Wu Chunyan,
Xie Dong,
Chen ChangORCID
Subject
Cancer Research,Oncology
Reference38 articles.
1. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers;Shigematsu;J Natl Cancer Inst,2005
2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012
3. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020
4. Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update;Hanna;J Clin Oncol,2017
5. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations;Passaro;J Thorac Oncol,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献